# Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00964132** · PHASE2 · UNKNOWN · sponsor: **NuRx Pharmaceuticals, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** NRX194204

## Key facts

- **NCT ID:** NCT00964132
- **Lead sponsor:** NuRx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2009-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00964132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00964132, "Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00964132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*